cytomegalovirus
Letermovir Prophylaxis Lowers CMV Risk in HCT Patients
The recently approved antiviral drug letermovir lowered the risk for clinically significant cytomegalovirus ...
FEBRUARY 23, 2018
FDA Approves Prevymis for CMV Prevention in Allo-HCT Patients
The FDA approved Merck's Prevymis, Merck for prophylaxis of cytomegalovirus infection and disease in adult ...
NOVEMBER 13, 2017
Load more